Citations

Clear

334 citation(s) found for "Jacobs, C".

Brace Yourselves: Outcomes of Ponseti Casting and Foot Abduction Orthosis Bracing in Idiopathic Congenital Talipes Equinovarus
Kuzma, Alexander L. , Talwalkar, Vishwas, Muchow, Ryan D. , Iwinski, Henry J. , Milbrandt, Todd A. , Walker, Janet L. , Jacobs, Cale A.

Mayo Clinic

Journal of Pediatric Orthopaedics | April 9, 2019 | Volume: 40 | Issue: 1 | Pages: e25-e29

10.1097/bpo.0000000000001380 | PMID 30969199 Get It

Background: Foot abduction orthoses (FAO) are believed to decrease recurrence following treatment of congenital talipes equinovarus (CTEV) as described by Ponseti. The purpose of this project is to examine the outcomes of FAO bracing following treatment by the Ponseti method in a cohort of idiopathic CTEV patients. Methods: After IRB approval, a cohort of patients aged 3 to 46 days with idiopathic CTEV was identified in a previous prospective study of brace compliance by family report and sensor. Dimeglio score and family demographic information were collected. Initial treatment was by the Ponseti method, with or without Achilles tenotomy. Following correction, patients had three months of full-time FAO bracing during which parents kept a log of compliance. Patients were followed until recurrence (need for further treatment) or age 5. Results: In total, 42 patients with 64 affected feet met the above criteria and were included in the final analysis. Twenty-six feet (40%) went on to develop recurrence requiring further treatment, including casting, bracing, or surgery. Because of poor tolerance of the original FAO, 20 feet were transitioned to an alternative FAO, and 14 of these (70%) went on to recur (P<0.01). The casting duration (P=0.02) had a statistically significant relationship to recurrence. Patients who were casted for 9 weeks or more had a higher rate of recurrence (57.1% vs. 27.8%; P=0.02). Age at treatment start, Dimeglio score, demographic factors, and compliance during full-time bracing, whether by report or sensor, did not show a significant relationship with recurrence. Conclusions: The study showed a statistically significant relationship between the difficulty of CTEV correction and the risk of recurrent deformity requiring treatment. This relationship could be used to provide prognostic information for patients’ families. Caregiver-reported compliance was not significantly related to recurrence. Level of Evidence: Level III—Prognostic Retrospective Cohort Study.
Vascular dysfunction—The disregarded partner of Alzheimer's disease
Sweeney, Melanie D. , Montagne, Axel , Nation, Daniel A. , Schneider, Lon S. , Chui, Helena C., Harrington, Michael G. , Pa, Judy , Law, Meng , Wang, Danny J.J. , Jacobs, Russell E. , Doubal, Fergus , Ramirez, Joel , Dichgans, Martin , Love, Seth , Bath, Philip M. , Markus, Hugh S. , Salman, Rustam Al‐Shahi , Kalaria, Rajesh N., Werring, David J. , Moskowitz, Michael A., Katušić, Zvonimir S. , Lazarov, Orly , Rehman, Jalees , Wellington, Cheryl L. , González, Héctor M. , Yuan, Chun , Lockhart, Samuel N. , Hughes, Timothy M. , Chen, Christopher , Sachdev, Perminder S. , O’Brien, John T. , Pantoni, Leonardo , Gustafson, Deborah , Biessels, Geert Jan , Wallin, Anders , Wong, Adrian , Passmore, Peter , Barkof, Frederick, Muller, Majon , Román, Gustavo C. , Hamel, Édith , Seshadri, Sudha , Buchem, Mark A. van , Arvanitakis, Zoe , Drewes, Lester R. , Hachinski, Vladimir , Wardlaw, Joanna M. , Kalaria, Raj N. , Dichgans, Martin , O'Brien, John Tiernan , Wardlaw, Joanna Marguerite , Seshadri, Sudha , Sachdev, Perminder S , Sagare, Abhay P. , Chui, Helena C. , Black, Sandra E. , Nedergaard, Maiken , Benveniste, Helene , Iadecola, Costantino , Allan, Stuart McRae , Quinn, Terence J , Carare, Roxana Octavia , Touyz, Rhian M. , Williams, Steven , Lutz, Sarah E. , Minshall, Richard D. , Davis, Thomas P. , Gonzalez, Hector M , Skoog, Ingmar , Biessels, Geert Jan , Smith, Eric Edward , Mok, Vincent , Breteler, Monique M.B. , Gottesman, Rebecca F. , Schneider, Julie A. , Finch, Caleb E. , Toga, Arthur W. , Zloković, Berislav V. , Al-Shahi Salman, Rustam , Werring, David John , Wang, Danny J J

Mayo Clinic

Alzheimer's & Dementia | January 11, 2019 | Volume: 15 | Issue: 1 | Pages: 158-167

10.1016/j.jalz.2018.07.222 | PMID 30642436 Get It

Abstract Increasing evidence recognizes Alzheimer's disease (AD) as a multifactorial and heterogeneous disease with multiple contributors to its pathophysiology, including vascular dysfunction. The recently updated AD Research Framework put forth by the National Institute on Aging–Alzheimer's Association describes a biomarker‐based pathologic definition of AD focused on amyloid, tau, and neuronal injury. In response to this article, here we first discussed evidence that vascular dysfunction is an important early event in AD pathophysiology. Next, we examined various imaging sequences that could be easily implemented to evaluate different types of vascular dysfunction associated with, and/or contributing to, AD pathophysiology, including changes in blood‐brain barrier integrity and cerebral blood flow. Vascular imaging biomarkers of small vessel disease of the brain, which is responsible for >50% of dementia worldwide, including AD, are already established, well characterized, and easy to recognize. We suggest that these vascular biomarkers should be incorporated into the AD Research Framework to gain a better understanding of AD pathophysiology and aid in treatment efforts.
Regorafenib dose optimization study (ReDOS): Randomized phase II trial to evaluate dosing strategies for regorafenib in refractory metastatic colorectal cancer (mCRC)–An ACCRU Network study.
Anderson, Daniel M. , Ahn, Daniel H. , Ciombor, Kristen K. , Jacobs, Nisha L. , Desnoyers, Rodwige J., Cleary, James M. , Meyers, Jeffrey P., Chiorean, E. Gabriela , Sloan, Jeffrey A., McCune, Jeannine S. , Lenz, Heinz Josef, Bekaii‐Saab, Tanios , Ou, Fang‐Shu , Boland, Patrick M. , Pedersen, Katrina S. , Barzi, Afsaneh , Lacouture, Mario E. , Grothey, Axel

Mayo Clinic

Journal of Clinical Oncology | January 2, 2019 | Volume: 36 | Issue: 4_suppl | Pages: 611-611

10.1200/jco.2018.36.4_suppl.611 Get It

611 Background: Regorafenib is an oral multikinase inhibitor with survival benefit in refractory mCRC patients (pts). Toxicities such as Palmar-plantar erythrodysesthesia syndrome (PPES), fatigue and hypertension (HTN) have limited its use. Despite absence of supportive data, various dosing or interval scheduling have been implemented into clinical practice. Methods: A randomized phase II study of regorafenib dose-escalation (Arm A: 80 mg/day, weekly dose escalation if no significant drug-related toxicities, up to 160 mg/day) vs. standard dose (Arm B: 160 mg/day) in pts with mCRC for 21 days of a 28-day cycle. Pts were randomized 1:1:1:1 to arms A1 and B1 (Pre-emptive Clobetasol for PPES); A2 and B2 (Reactive Clobetasol). The primary endpoint was the proportion of patients who completed 2 cycles of treatment and initiated the 3rd in Arm A (Pooled A1 + A2) vs. Arm B (Pooled B1 + B2). Superiority for Arm A was to be declared if the one-sided p-value calculated using Fisher’s exact method was less than 0.2. Results: From June 2015 to June 2017, 123 pts were randomized with 116 (A = 54, B = 62) evaluable for the primary endpoint. Demographic data were well balanced with overall median age of 61yrs (range: 29-81), M/F (61/39%) and ECOG PS 0/1 (37/63%) and KRAS MT/WT/UNK (47/44/9%).The study met its primary endpoint with 43% of pts on Arm A initiating the 3rd vs. only 25% of pts Arm B [one-sided p-value 0.028]. Median Overall Survival (OS) was improved in Arm A vs. Arm B (9.0 mos vs. 5.9 mos; p = 0.094). Median Progression Free Survival (PFS) was 2.5 mos for Arm A vs. 2.0 mos for Arm B (p=0.553). Overall rates of grade 3/4 toxicity were more favorable for Arm A vs. Arm B (% PPES 15 vs. 16, HTN 7 vs. 15 and fatigue 13 vs. 18, respectively). Multiple QOL parameters were improved in A vs. B primarily at week 2 of the first cycle. Conclusion: A strategy with weekly dose escalation of regorafenib from 80 mg to 160 mg/day was found to be superior to a starting dose of 160 mg/day. These results establish a new standard for optimizing regorafenib dosing. Further data on outcomes of preemptive vs. reactive clobetasol strategies are undergoing analysis and will be presented later. Clinical trial information: NCT02368886.
Novel zebrafish behavioral assay to identify modifiers of the rapid, nongenomic stress response
Lee, Han , Schwab, Tanya L., Sigafoos, Ashley N. , Gauerke, Jennifer L., Krug, Randall G. , Serres, MaKayla R., Jacobs, Dakota C., Cotter, Ryan P. , Das, Biswadeep , Petersen, Morgan O. , Daby, Camden L. , Urban, Rhianna , Berry, Bethany C. , Lee, Han B , Urban, Rhianna M, Clark, Karl J , Serres, MaKayla R., Clark, Karl J. , Cotter, Ryan P

Mayo Clinic

Genes, Brain and Behavior | December 27, 2018 | Volume: 18 | Issue: 2 | Pages: No page available

10.1111/gbb.12549 | PMID 30588759 Get It

When vertebrates face acute stressors, their bodies rapidly undergo a repertoire of physiological and behavioral adaptations, which is termed the stress response. Rapid changes in heart rate and blood glucose levels occur via the interaction of glucocorticoids and their cognate receptors following hypothalamic‐pituitary‐adrenal axis activation. These physiological changes are observed within minutes of encountering a stressor and the rapid time domain rules out genomic responses that require gene expression changes. Although behavioral changes corresponding to physiological changes are commonly observed, it is not clearly understood to what extent hypothalamic‐pituitary‐adrenal axis activation dictates adaptive behavior. We hypothesized that rapid locomotor response to acute stressors in zebrafish requires hypothalamic‐pituitary‐interrenal (HPI) axis activation. In teleost fish, interrenal cells are functionally homologous to the adrenocortical layer. We derived eight frameshift mutants in genes involved in HPI axis function: two mutants in exon 2 ofmc2r(adrenocorticotropic hormone receptor), five in exon 2 or 5 ofnr3c1(glucocorticoid receptor [GR]) and two in exon 2 ofnr3c2(mineralocorticoid receptor [MR]). Exposing larval zebrafish to mild environmental stressors, acute changes in salinity or light illumination, results in a rapid locomotor response. We show that this locomotor response requires a functioning HPI axis via the action ofmc2rand the canonical GR encoded bynr3c1gene, but not MR (nr3c2). Our rapid behavioral assay paradigm based on HPI axis biology can be used to screen for genetic and environmental modifiers of the hypothalamic‐pituitary‐adrenal axis and to investigate the effects of corticosteroids and their cognate receptor interactions on behavior.
Aspirin, NSAIDs, and Glioma Risk: Original Data from the Glioma International Case–Control Study and a Meta-analysis
Amirian, E. Susan , Ostrom, Quinn T. , Armstrong, Georgina , Lai, Rose , Gu, Xiangjun, Jacobs, Daniel I. , Jalali, Ali , Claus, Elizabeth B. , Barnholtz‐Sloan, Jill S. , Il’yasova, Dora , Schildkraut, Joellen M. , Ali‐Osman, Francis, Sadetzki, Siegal , Jenkins, Robert B. , Bernstein, Jonine L. , Merrell, Ryan , Wrensch, Margaret , Johansen, Christoffer , Houlston, Richard S. , Shete, Sanjay , Melin, Beatrice , Bondy, Melissa L. , Houlston, Richard S , Amos, Christopher I , Barnholtz-Sloan, Jill S , Armstrong, Georgina , Lachance, Daniel Honore , Olson, Sara H. , Amos, Christopher I. , Ostrom, Quinn T

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | November 27, 2018 | Volume: 28 | Issue: 3 | Pages: 555-562

10.1158/1055-9965.epi-18-0702 | PMID 30482874 Get It

Abstract Background: There have been few studies of sufficient size to address the relationship between glioma risk and the use of aspirin or NSAIDs, and results have been conflicting. The purpose of this study was to examine the associations between glioma and aspirin/NSAID use, and to aggregate these findings with prior published studies using meta-analysis. Methods: The Glioma International Case-Control Study (GICC) consists of 4,533 glioma cases and 4,171 controls recruited from 2010 to 2013. Interviews were conducted using a standardized questionnaire to obtain information on aspirin/NSAID use. We examined history of regular use for ≥6 months and duration-response. Restricted maximum likelihood meta-regression models were used to aggregate site-specific estimates, and to combine GICC estimates with previously published studies. Results: A history of daily aspirin use for ≥6 months was associated with a 38% lower glioma risk, compared with not having a history of daily use [adjusted meta-OR = 0.62; 95% confidence interval (CI), 0.54–0.70]. There was a significant duration-response trend (P = 1.67 × 10−17), with lower ORs for increasing duration of aspirin use. Duration-response trends were not observed for NSAID use. In the meta-analysis aggregating GICC data with five previous studies, there was a marginally significant association between use of aspirin and glioma (mOR = 0.84; 95% CI, 0.70–1.02), but no association for NSAID use. Conclusions: Our study suggests that aspirin may be associated with a reduced risk of glioma. Impact: These results imply that aspirin use may be associated with decreased glioma risk. Further research examining the association between aspirin use and glioma risk is warranted.
GENE-11. SMALL TERMINAL ALTERATIONS AND ALTERNATIVE LENGTHENING OF TELOMERES ARE A FEATURE OF IDH-MUTANT, 1p/19q NON-CODELETED GLIOMAS
Yamada, Seiji , Jacobs, Joshua , Decker, Paul A. , Kosel, Matt, Caron, Alissa, Halder, Chandralekha, Ruiz, Vanessa , Kipp, Benjamin R. , Voss, Jesse S. , Vaubel, Rachel, Jenkins, Robert B. , Brown, Desmond , Praska, Corinne , Kollmeyer, Thomas M. , Decker, Paul A. , Kosel, Matthew , Giannini, Caterina

Mayo Clinic

Neuro-Oncology | November 5, 2018 | Volume: 20 | Issue: suppl_6 | Pages: vi105-vi105

10.1093/neuonc/noy148.438 Get It

TMIC-36. LOCAL TISSUE BIOMARKERS OF RESPONSE TO THERAPY FOR GLIOBLASTOMA
Olson, Ian , Jacobs, Joshua , Rajani, Karishma , Macura, Slobodan , Sarkaria, Jann N. , Burns, Terry C.

Mayo Clinic

Neuro-Oncology | November 5, 2018 | Volume: 20 | Issue: suppl_6 | Pages: vi264-vi264

10.1093/neuonc/noy148.1095 Get It

Task Force 3: Disclosure of Relationships With Commercial Interests: Policy for Educational Activities and Publications
Lindsay, Bruce D., Bellande, Bruce J., Nishimura, Rick A., Shah, Pravin M., Jackson, Marcia, Rahimtoola, Shahbudin H., Jacobs, Alice K. , Fonarow, Gregg C. , Annex, Brian Herb , Fuster, Valentı́n , Gibbons, Raymond J.

Mayo Clinic

Circulation | September 29, 2018 | Volume: 110 | Issue: 16 | Pages: 2524-2528

10.1161/circ.110.16.2524 Get It

Rapid Molecular Diagnostics to Inform Empiric Use of Ceftazidime/Avibactam and Ceftolozane/Tazobactam Against Pseudomonas aeruginosa: PRIMERS IV
Tran, Thuy Tien T., Hujer, Andrea M. , Hill, Carol , Hujer, Kristine M., Mediavilla, José R. , Pérez, Federico , Farmer, Michael , Pitzer, Kelsey, Wilson, Brigid , Kreiswirth, Barry N. , Patel, Robin , Chen, Liang , Fowler, Vance G. , Chambers, Henry F. , Chen, Liang , Patel, Robin , Evans, Scott R , Evans, Scott , Manca, Claudia , Domitrovic, Tatiana , Farmer, Michael, Kreiswirth, Barry N , Jacobs, Michael R. , Fowler, Vance G. , Bonomo, Robert A.

Mayo Clinic

Clinical Infectious Diseases | September 18, 2018 | Volume: 68 | Issue: 11 | Pages: 1823-1830

10.1093/cid/ciy801 | PMID 30239599 Get It

AbstractBackgroundOvercoming β-lactam resistance in pathogens such as Pseudomonas aeruginosa is a major clinical challenge. Rapid molecular diagnostics (RMDs) have the potential to inform selection of empiric therapy in patients infected by P. aeruginosa.MethodsIn this study, we used a heterogeneous collection of 197 P. aeruginosa that included multidrug-resistant isolates to determine whether 2 representative RMDs (Acuitas Resistome test and VERIGENE gram-negative blood culture test) could identify susceptibility to 2 newer β-lactam/β-lactamase inhibitor (BL-BLI) combinations, ceftazidime/avibactam (CZA) and ceftolozane/tazobactam (TOL/TAZO).ResultsWe found that the studied RMD platforms were able to correctly identify BL-BLI susceptibility (susceptibility sensitivity, 100%; 95% confidence interval [CI], 97%, 100%) for both BLs-BLIs. However, their ability to detect resistance to these BLs-BLIs was lower (resistance sensitivity, 66%; 95% CI, 52%, 78% for TOL/TAZO and 33%; 95% CI, 20%, 49% for CZA).ConclusionsThe diagnostic platforms studied showed the most potential in scenarios where a resistance gene was detected or in scenarios where a resistance gene was not detected and the prevalence of resistance to TOL/TAZO or CZA is known to be low. Clinicians need to be mindful of the benefits and risks that result from empiric treatment decisions that are based on resistance gene detection in P. aeruginosa, acknowledging that such decisions are impacted by the prevalence of resistance, which varies temporally and geographically.